At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 606 enrolled
Drug / intervention
Ozanimod +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Induction Study #2 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
In Brief
A Phase 3 clinical trial evaluating Ozanimod and Placebo for Crohn Disease. Completed, enrolled 606 participants across 368 sites in 31 countries.
Detailed Summary
This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCrohn Disease
CountriesAustralia, Austria, Bulgaria, Canada, China, Colombia, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Israel, Lithuania, Netherlands, Poland, Portugal, Russia, Senegal, Serbia, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Taiwan, Turkey (Türkiye), Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartMar 2018
Primary CompletionNov 2023
TodayJul 2026
First PostedFeb 22, 2018
Enrollment StartMar 7, 2018
Primary CompletionNov 21, 2023
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 8.4 years ago
Interventions
Ozanimoddrug
Specified dose on specified days
Placeboother
Specified dose on specified days